Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia.
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2013
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms STAR
- Sponsors Bayer
- 08 Jul 2009 Actual patient number (6) added as reported by ClinicalTrials.gov.
- 08 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 16 Jun 2009 Planned end date changed from Oct 2009 to Jun 2009 as reported by ClinicalTrials.gov.